Willis Towers Watson appoints Mary O’Connor to lead Client and Business Development in Great Britain
Dec 14, 2016 13:03 pm UTC| Business
LONDON, Dec. 14, 2016 -- Willis Towers Watson is pleased to announce that Mary O'Connor will lead the Client and Business Development function for Willis Towers Watson Great Britain. Mary also continues to co-lead the...
Dec 14, 2016 13:00 pm UTC| Business
RedHill and its co-development partner, IntelGenxCorp. (IntelGenx), have signed a definitive agreement with Pharmatronic Co., granting an exclusive license to commercialize the acute migraine drug RIZAPORT® in South...
InvisibleShield Introduces Glass+ Luxe and Glass+ Privacy Screen Protectors for iPhone
Dec 14, 2016 13:00 pm UTC| Business
SALT LAKE CITY, Dec. 14, 2016 -- InvisibleShield®, the leading global brand and innovator in screen protection, today expanded its lineup of Glass+ tempered glass screen protectors by announcing Glass+ Luxe™ and Glass+...
Postman Announces Postman Pro: Complete API Toolchain for Developers & Developer Teams
Dec 14, 2016 13:00 pm UTC| Business
SAN FRANCISCO, Dec. 14, 2016 -- Postman, provider of the most popular API toolchain available, today announced a major update to its innovative developer product, Postman Pro. In limited release since early this year as...
Dec 14, 2016 13:00 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., Dec. 14, 2016 -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today announced that the...
Argos Therapeutics Enters into Strategic Research Agreement with Personalis, Inc.
Dec 14, 2016 13:00 pm UTC| Business
DURHAM, N.C., Dec. 14, 2016 -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis®...
Ohr Pharmaceutical Announces Closing of Public Offering of Common Stock and Warrants
Dec 14, 2016 13:00 pm UTC| Business
NEW YORK, Dec. 14, 2016 -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it has closed its previously announced public offering of common stock and...